Delivery Order SPE2DB20D1100-SPE2DB24FA7G2
- Not listed
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,428.66 firm fixed-price contract is for the delivery of Clindamycin Phosphate 1% Foam, a topical antibiotic medication, with a period of performance through October 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin Phosphate 1% Foam, 100 grams, with a ceiling value of $1,811.64 and a period of performance through June 30, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Clindamycin Phosphate 1% Foam 100GM with a ceiling value of $1,744.22. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by October 23, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,309.22 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam in 50-gram units. This competitively awarded, firm fixed-price delivery order was issued on August 22, 2025, with an ultimate completion date of August 25, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,323.00 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM on August 20, 2025, with completion expected by August 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The pharmaceutical product will be performed at the vendor's corporate office location in...
- The Defense Logistics Agency awarded a $1,620.04 delivery order to AmerisourceBergen Drug Corp on December 22, 2025, for the supply of Clindamycin Phosphate 1% Foam in 50-gram units. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competitive procurement. The contract is scheduled for ultimate completion on December 23, 2025, with performance occurring at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $25,629.43 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam 100GM on September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to the pharmaceutical distributor. The products will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This delivery order falls under...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,206.73 fixed-price contract is for the delivery of Clindamycin Phosphate 1% Foam, a topical antibiotic medication, with a completion date of December 18, 2024. The contract is not associated with a larger vehicle or set-aside program. However, AmerisourceBergen holds a significant $999,999,999 Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM with a ceiling value of $4,383.79 under a firm fixed-price contract structure. This delivery order, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM with a ceiling value of $2,408.10 under a firm fixed price contract type. This delivery order, awarded on November 5, 2025, represents a non-set-aside competitive award and is set for completion by November 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB24FA7G2Delivery Order
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The delivery order, valued at $1,437.66, is for the supply of 4563957329 - CLINDAMYCIN PHOSPHATE 1% FOAM 100GM. The contract has a period of performance ending on March 14, 2024. This delivery order falls under a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corporation, valued up to $999,999,999.00 and running through December 31, 2025. The IDC serves as the primary contract vehicle for AmerisourceBergen to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. No set-aside designation was used for this contract award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 3/13/24 |